Open Access. Powered by Scholars. Published by Universities.®
Biochemistry, Biophysics, and Structural Biology Commons™
Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Pharmacology, Toxicology and Environmental Health (47)
- Microbiology (22)
- Molecular Biology (12)
- Structural Biology (10)
- Biochemistry (9)
-
- Chemistry (9)
- Medicinal Chemistry and Pharmaceutics (9)
- Medicinal-Pharmaceutical Chemistry (9)
- Physical Sciences and Mathematics (9)
- Virology (9)
- Medicine and Health Sciences (6)
- Immunology and Infectious Disease (2)
- Biophysics (1)
- Cell Biology (1)
- Cell and Developmental Biology (1)
- Computational Biology (1)
- Diseases (1)
- Genetics and Genomics (1)
- Immunity (1)
- Immunology of Infectious Disease (1)
- Immunoprophylaxis and Therapy (1)
- Medical Biochemistry (1)
- Medical Biophysics (1)
- Medical Sciences (1)
- Nervous System Diseases (1)
- Keyword
-
- Humans (26)
- HIV Protease (25)
- HIV Protease Inhibitors (24)
- HIV-1 (23)
- Models, Molecular (21)
-
- Crystallography, X-Ray (20)
- Binding Sites (16)
- Protein Conformation (15)
- Drug Resistance, Viral (14)
- Mutation (13)
- Substrate Specificity (11)
- Molecular Sequence Data (10)
- Structure-Activity Relationship (10)
- Thermodynamics (9)
- Amino Acid Sequence (8)
- Drug Design (7)
- Molecular Structure (7)
- Computer Simulation (6)
- Sulfonamides (6)
- Animals (5)
- Catalytic Domain (5)
- Drug Resistance, Multiple, Viral (5)
- Gag Gene Products, Human Immunodeficiency Virus (5)
- Hydrogen Bonding (5)
- Kinetics (5)
- Ligands (5)
- Protein Binding (5)
- Water (5)
- Aprotinin (4)
- Cell Line (4)
- File Type
Articles 61 - 62 of 62
Full-Text Articles in Biochemistry, Biophysics, and Structural Biology
Resilience To Resistance Of Hiv-1 Protease Inhibitors: Profile Of Darunavir, Eric Lefebvre, Celia A. Schiffer
Resilience To Resistance Of Hiv-1 Protease Inhibitors: Profile Of Darunavir, Eric Lefebvre, Celia A. Schiffer
Celia A. Schiffer
The current effectiveness of HAART in the management of HIV infection is compromised by the emergence of extensively cross-resistant strains of HIV-1, requiring a significant need for new therapeutic agents. Due to its crucial role in viral maturation and therefore HIV-1 replication and infectivity, the HIV-1 protease continues to be a major development target for antiretroviral therapy. However, new protease inhibitors must have higher thresholds to the development of resistance and cross-resistance. Research has demonstrated that the binding characteristics between a protease inhibitor and the active site of the HIV-1 protease are key factors in the development of resistance. More …
Structural Analysis Of Human Immunodeficiency Virus Type 1 Crf01_Ae Protease In Complex With The Substrate P1-P6., Rajintha Bandaranayake, Moses Prabu-Jeyabalan, Junko Kakizawa, Wataru Sugiura, Celia Schiffer
Structural Analysis Of Human Immunodeficiency Virus Type 1 Crf01_Ae Protease In Complex With The Substrate P1-P6., Rajintha Bandaranayake, Moses Prabu-Jeyabalan, Junko Kakizawa, Wataru Sugiura, Celia Schiffer
Celia A. Schiffer
The effect of amino acid variability between human immunodeficiency virus type 1 (HIV-1) clades on structure and the emergence of resistance mutations in HIV-1 protease has become an area of significant interest in recent years. We determined the first crystal structure of the HIV-1 CRF01_AE protease in complex with the p1-p6 substrate to a resolution of 2.8 A. Hydrogen bonding between the flap hinge and the protease core regions shows significant structural rearrangements in CRF01_AE protease compared to the clade B protease structure.